Stricter compliance procedures eyed by Indian pharma

09/29/2013 | Business Standard (India)

Top Indian drugmakers say they need stricter compliance procedures and greater investment in quality to maintain their share in the global market amid concerns about increasing global enforcements. "Domestic companies represent a significant part of the global drug industry and, therefore, there is an increase in the scrutiny of these companies," Biocon Chairman and Managing Director Kiran Mazumdar-Shaw said. Audits are more frequent than earlier periodic reviews because of the U.S. FDA's presence in the country now, she said.

View Full Article in:

Business Standard (India)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX